Fritextsökning
Innehållstyper
-
Pfizer’s record year – topped the $100 billion mark
In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...
-
Genes from Neanderthals can affect the correct drug dosage
A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for th...
-
FDA-beslut: AZ:s nasala influensavaccin får tas av patienten själv
Astra Zenecas nasala influensavaccin Flumist har godkänts för självadministrering i USA. Det är därmed det första influensavaccinet i USA som inte behöver ges av en vårdgivare.
-
Öppen frågestund: Regulatory Opportunities for Rare Diseases/Orphan Products in US and EU
Anmäl dig till vår nästa session av Office Hours den 28 februari klockan 15:00 (svensk tid), en öppen frågestund om utveckling av särläkemedel (orphan drugs).
-
Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas
Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...
-
Radioactive tracer to measure effect of drug towards Crohn’s disease
A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...
-
Nytt läkemedel mot schizofreni godkänt i USA
För första gången på flera decennier har en ny typ av läkemedel mot schizofreni godkänts av den amerikanska läkemedelsmyndigheten FDA.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage...
-
Nässprej för behandling av anafylaxi godkänd i USA
Den amerikanska läkemedelsmyndigheten, FDA, har gett tummen upp till en ny typ av nässprej. Nässprejen är ett injektionsfritt alternativ för behandling av akuta...
-
GSK pays 2.2 billion dollars to settle Zantac lawsuits
British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...
-
Donanemab godkänns i Storbritannien – men anses för dyrt för skattebetalarna
Eli Lillys alzheimerläkemedel donanemab godkänns i Storbritannien – men lär ändå inte bli tillgängligt för vanliga patienter. Orsaken är att behandlingen bedöms...
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...
-
A vaccine the world is waiting for: “It can change the lives of many”
A Solna laboratory is developing a vaccine that could save the lives of countless children in low- and middle-income countries. “Working on something that can m...
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
No longer afraid of the dentist.
Teaching robot with piezo technology
-
Karriärcoachen: ”Inom industrin lärde jag mig mer om mig som person”
Det blir allt vanligare att lämna akademin för näringslivet inom life science. Men det är en omställning som kan innebära vissa svårigheter, påpekar karriärcoac...
-
Ozempic may benefit hip replacement surgery
The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...
-
Column: ”Cheating with pea flowers and does it matter whether you are right?”
Is it possible to forgive shortcuts or outright cheating in science - if it turns out that the researcher was ultimately right? Anna Törner discuss this topic in a column.
-
Acquisition of consulting company Key2Compliance
The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.
-
Trends and overview: ELRIG "Robotics and Automation"
Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic
-
Mathias Uhlén’s protein atlas is recognised as a global resource
The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...
-
Stor kongress om framtidsutsikter igång i Lund
Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
The Swedish Academy of Sciences: “We have too many researchers”
Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.